Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cartesian Therapeutics (RNAC) Non Operating Income (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Non Operating Income for 11 consecutive years, with -$2.0 million as the latest value for Q4 2025.

  • Quarterly Non Operating Income rose 94.15% to -$2.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.0 million through Dec 2025, up 93.95% year-over-year, with the annual reading at -$2.0 million for FY2025, 93.95% up from the prior year.
  • Non Operating Income for Q4 2025 was -$2.0 million at Cartesian Therapeutics, down from -$5000.0 in the prior quarter.
  • The five-year high for Non Operating Income was $508000.0 in Q1 2024, with the low at -$34.3 million in Q4 2024.
  • Average Non Operating Income over 5 years is -$2.3 million, with a median of $154000.0 recorded in 2022.
  • The sharpest move saw Non Operating Income surged 25200.0% in 2023, then plummeted 55206.45% in 2024.
  • Over 5 years, Non Operating Income stood at $9000.0 in 2021, then soared by 1844.44% to $175000.0 in 2022, then tumbled by 135.43% to -$62000.0 in 2023, then tumbled by 55206.45% to -$34.3 million in 2024, then surged by 94.15% to -$2.0 million in 2025.
  • According to Business Quant data, Non Operating Income over the past three periods came in at -$2.0 million, -$5000.0, and -$34.3 million for Q4 2025, Q2 2025, and Q4 2024 respectively.